Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green tea mist tested against COVID lung inflammation in cancer patients

NCT ID NCT06924749

Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested whether inhaling a green tea extract called EGCG could help cancer patients with moderate-to-severe COVID-19 pneumonia. 111 participants received either EGCG mist or a placebo three times daily for 7 days. The study looked at lung CT scan improvements, symptom relief, and safety. EGCG is known for anti-inflammatory and antiviral effects, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EGCG (epigallocatechin-3-gallate), a green tea extract, given as an inhaled mist
What this could lead to
If it works, this could offer a safe, plant-based treatment option for COVID-19 pneumonia in cancer patients, reducing lung inflammation and improving recovery.
What could go wrong
This is a small, completed Phase 2 trial with no published results yet. The benefit may be modest or not better than standard care, and the findings may not apply to non-cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

111 people

The number who actually took part.

Started

Jun 2023

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed malignant tumors by pathology or cytology * COVID-19 with a confirmed positive polymerase chain reaction or antigen test result for SARS-CoV-23 * moderate-to-severe COVID-19 pneumonia (defined as any radiographic evidence of pulmonary infiltrates and oxygen saturation \>94% on room air) * Pulmonary function of the patient can be treated with aerosol inhalation for 7 days Exclusion Criteria: * Current or recent progresses rapidly and may develop into a Critical illness with coronavirus in a short period of time * Caused by other viruses such as cytomegalovirus, as well as pneumocystis pneumonia, pulmonary edema, aspiration pneumonia and acute interstitial pneumonia * Any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the Investigator would preclude the participant from adhering to the protocol or would increase the risk associated with study participation * known allergy or hypersensitivity to EGCG

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer COVID-19 interstitial lung disease non-specific interstitial pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer patients Pneumonia, interstitial

Contacts and locations

Locations

  • Hanxi Zhao

    Jinan, Shandong, Shandong Cancer Hospital, China

  • Shan Dong cancer hospital and institute

    Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.